natgillin/translations-raw huggingface dataset:
Incresync fås som filmovertrukne tabletter i styrkerne 25 mg/30 mg, 25 mg/45 mg, 12,5 mg/30 mg og 12,5 mg/45 mg. 
For the different dose regimens Incresync is available in strengths of 25 mg/30 mg, 25 mg/45 mg, 12.5 mg/30 mg and 12.5 mg/45 mg film-coated tablets.
Gennemsnitlig HbA1c ved baseline (%) (SD) 
Mean baseline HbA1c (%) (SD)
Der er rapporter om, at samtidig administration af pioglitazon og gemfibrozil (en hæmmer af cytokrom P450 2C8) har resulteret i en tredobling af AUC for pioglitazon. 
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC for pioglitazone.
- Stærke og vedvarende smerter i maven, som kan stråle ud i ryggen, samt kvalme og opkastning. 
- Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).
I de fleste kliniske studier blev der observeret en reduktion af niveauerne af totalplasmatriglycerider, frie fedtsyrer og en øgning i HDL-kolesterolniveauer sammenlignet med placebo. 
In most clinical studies, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo with small, but not clinically significant, increases in LDL-cholesterol levels.
Incresync 12,5 mg/30 mg filmovertrukne tabletter Incresync 12,5 mg/45 mg filmovertrukne tabletter Incresync 25 mg/30 mg filmovertrukne tabletter Incresync 25 mg/45 mg filmovertrukne tabletter 
Incresync 12.5 mg/30 mg film-coated tablets Incresync 12.5 mg/45 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets
Incresync 12,5 mg/30 mg filmovertrukne tabletter Incresync 12,5 mg/45 mg filmovertrukne tabletter Incresync 25 mg/30 mg filmovertrukne tabletter Incresync 25 mg/45 mg filmovertrukne tabletter alogliptin/pioglitazon 
Incresync 12.5 mg/30 mg film-coated tablets Incresync 12.5 mg/45 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets alogliptin/pioglitazone
Der er desuden indberettet tilfælde af leverfunktionssvigt, herunder leversvigt, efter markedsføring af alogliptin. 
Postmarketing reports of hepatic dysfunction including hepatic failure have been received for alogliptin.
Bioækvivalensstudier viser imidlertid, at Incresync, filmovertrukne tabletter er bioækvivalente med tilsvarende doser af alogliptin og pioglitazon givet samtidigt som separate tabletter. 
However, the results of bioequivalence studies have demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.
Det er ikke nødvendigt at justere dosis for Incresync hos patienter med let nedsat nyrefunktion (kreatininclearance (CrCl) > 50 til ≤ 80 ml/min) (se pkt. 
For patients with mild renal impairment (creatinine clearance (CrCl) > 50 to ≤ 80 mL/min), no dose adjustment of Incresync is necessary (see section 5.2).
INFORMATION I BRAILLE-SKRIFT Incresync 25 mg/45 mg 
INFORMATION IN BRAILLE Incresync 25 mg/45 mg
4.4 og 4.8) - Hjerteinsufficiens eller tidligere hjerteinsufficiens (NYHA-klasse I til IV, se pkt. 
Cardiac failure or history of cardiac failure (NYHA stages I to IV; see section 4.4) Hepatic impairment (see section 4.4)
Alogliptin som tillæg til pioglitazon 
Alogliptin as add-on therapy to pioglitazone
Bioækvivalensstudier af raske forsøgspersoner viser, at Incresync, filmovertrukne--tabletter er bioækvivalente med tilsvarende doser af alogliptin og pioglitazon givet samtidigt som separate tabletter. 
The results of bioequivalence studies in healthy subjects demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.
Incresync anbefales ikke til patienter med svært nedsat nyrefunktion eller med dialysekrævende terminal nyresygdom (se pkt. 
Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis (see section 4.2).
INFORMATION I BRAILLE-SKRIFT Incresync 12,5 mg/30 mg 
INFORMATION IN BRAILLE Incresync 12.5 mg/30 mg
INFORMATION I BRAILLE-SKRIFT Incresync 12,5 mg/45 mg 
INFORMATION IN BRAILLE Incresync 12.5 mg/45 mg
Efter markedsføring er der set sjældne tilfælde af forhøjede leverenzymtal og hepatocellulær dysfunktion. 
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience.
Der er set henholdsvis en forøgelse og en nedsættelse af plasmakoncentrationen af pioglitazon ved samtidig administration af pioglitazon og gemfibrozil (en hæmmer af cytochrom P450 2C8) eller rifampicin (en induktor af cytokrom P450 2C8) (se pkt. 
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the serum concentration of pioglitazone (see section 4.5).
INFORMATION I BRAILLE-SKRIFT Incresync 25 mg/30 mg 
INFORMATION IN BRAILLE Incresync 25 mg/30 mg
De tegn, du skal være opmærksom på, er kløe, en følelse af varme især i hovedbund, mund, hals, håndflader og fodsåler (Stevens-Johnsons syndrom).hvis du lider af hjertesvigt eller tidligere har haft hjertesvigt. 
Additional symptoms may include general itching and feeling of heat especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome).
cyster og polypper) blærecancer ikke almindelig 
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon
Antal patienter (%) Alogliptin 25 mg 
Alogliptin 25 mg
Rød jernoxid (E172) 
Iron oxide yellow (E172)
Dette sker fortrinsvis via cytokrom P450 2C8, selvom andre isoformer kan være involveret i mindre grad. Tre af de seks identificerede pioglitazon-metabolitter er aktive (M-II, M-III og M-IV). 
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Røde, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og "25/45" trykt i gråt på den ene side. 
Red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/45” printed in grey ink on one side.
Nedsat leverfunktion Incresync må ikke gives til patienter med nedsat leverfunktion (se pkt. 
No dose adjustment of Incresync for patients with mild renal impairment is necessary (see section 4.2).
Den samlede forekomst af episoder med svær hypoglykæmi var på samme niveau hos patienter behandlet med 25 mg alogliptin eller 12,5 mg alogliptin, og dette niveau var lavere end forekomsten hos patienter behandlet med aktiv kontrol eller placebo (henholdsvis 0,1 %, 0,1 %, 0,4 % og 0,4 %). 
and lower than the incidence in patients treated with active-control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively).
- Incresync 25 mg/45 mg filmovertrukne tabletter (tabletter) er røde, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"25/45" trykt i gråt på den ene side. 
- Incresync 25 mg/45 mg film-coated tablets (tablets) are red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “25/45” printed in grey ink on one side.
Udseende og pakningstørrelser - Incresync 25 mg/30 mg filmovertrukne tabletter (tabletter) er ferskenfarvede, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"25/30" trykt i gråt på den ene side. 
What Incresync looks like and contents of the pack - Incresync 25 mg/30 mg film-coated tablets (tablets) are peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “25/30” printed in grey ink on one side.
Incresync 25 mg/30 mg filmovertrukne tabletter 
Incresync 25 mg/30 mg film-coated tablets
Efter markedsføring har der været spontane indberetninger om overfølsomhedsreaktioner hos patienter behandlet med pioglitazon. 
Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria.
Incresync 25 mg/45 mg filmovertrukne tabletter 
Incresync 25 mg/45 mg film-coated tablets
Hver 25 mg/45 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 25 mg alogliptin og 45 mg pioglitazon. 
Each 25 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 45 mg pioglitazone.
25 mg/30 mg filmovertrukne tabletter 
25 mg/30 mg film-coated tablets
12,5 mg/45 mg filmovertrukne tabletter 
12.5 mg/45 mg film-coated tablets
Gennemsnitlig ændring i HbA1c fra baseline (%)† 
Mean change from baseline in HbA1c (%)† (SE)
Hver 12,5 mg/45 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 12,5 mg alogliptin og 45 mg pioglitazon. 
Each 12.5 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 45 mg pioglitazone.
25 mg/45 mg filmovertrukne tabletter 
25 mg/45 mg film-coated tablets
Lever og galdeveje leverfdysunktion, herunder leversvigt ikke kendt 
Hepatobiliary disorders hepatic dysfunction including hepatic failure not known
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke kan tåle visse sukkerarter. 
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Incresync.
Incresync 12,5 mg/30 mg filmovertrukne tabletter 
Incresync 12.5 mg/30 mg film-coated tablets
Farmakoterapeutisk klassifikation: Antidiabetika; komb. 
Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs.
Incresync 12,5 mg/45 mg filmovertrukne tabletter 
Incresync 12.5 mg/45 mg film-coated tablets
- Incresync 12,5 mg/30 mg filmovertrukne tabletter (tabletter) er svagt ferskenfarvede, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"12.5/30" trykt i rødt på den ene side. 
- Incresync 12.5 mg/30 mg film-coated tablets (tablets) are pale peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “12.5/30” printed in red ink on one side.
Det skal du vide, før du begynder at tage Incresync Sådan skal du tage Incresync Bivirkninger 
What Incresync is and what it is used for What you need to know before you take Incresync How to take Incresync
Hver 25 mg/30 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 25 mg alogliptin og 30 mg pioglitazon. 
Each 25 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 30 mg pioglitazone.
Blæk til prægning 12,5 mg/30 mg filmovertrukne tabletter 
Printing ink 12.5 mg/30 mg film-coated tablets
Hver tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 12,5 mg alogliptin og 30 mg pioglitazon. 
Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 30 mg pioglitazone.
Hver tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 25 mg alogliptin og 45 mg pioglitazon. 
Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 45 mg pioglitazone.
- Incresync 12,5 mg/45 mg filmovertrukne tabletter (tabletter) er svagt røde, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"12.5/45" trykt i rødt på den ene side. 
- Incresync 12.5 mg/45 mg film-coated tablets (tablets) are pale red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “12.5/45” printed in red ink on one side.
Svagt ferskenfarvede, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og "12.5/30" trykt i rødt på den ene side. 
Pale peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “12.5/30” printed in red ink on one side.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 25 mg alogliptin (som benzoat) og 45 mg pioglitazon (som hydrochlorid). 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg alogliptin (as benzoate) and 45 mg pioglitazone (as hydrochloride).
Hver tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 12,5 mg alogliptin og 45 mg pioglitazon. 
Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 45 mg pioglitazone.
LÆGEMIDLETS NAVN Incresync 25 mg/45 mg tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/45 mg tablets alogliptin/pioglitazone
Tabel 1: Bivirkninger 
Possible side effects
Hver 12,5 mg/30 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 12,5 mg alogliptin og 30 mg pioglitazon. 
Each12.5 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 30 mg pioglitazone.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 30 mg pioglitazon (som hydrochlorid). 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 30 mg pioglitazone (as hydrochloride).
LÆGEMIDLETS NAVN Incresync 12,5 mg/45 mg tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/45 mg tablets alogliptin/pioglitazone
Hver tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende til 25 mg alogliptin og 30 mg pioglitazon. 
Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 30 mg pioglitazone.
LÆGEMIDLETS NAVN Incresync 25 mg/30 mg tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/30 mg tablets alogliptin/pioglitazone
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 12,5 mg alogliptin (som benzoat) og 45 mg pioglitazon (som hydrochlorid). 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 45 mg pioglitazone (as hydrochloride).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 25 mg alogliptin (som benzoat) og 30 mg pioglitazon (som hydrochlorid). 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg alogliptin (as benzoate) and 30 mg pioglitazone (as hydrochloride).
Ferskenfarvede, runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"25/30" trykt i gråt på den ene side. 
Peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/30” printed in grey ink on one side.
LÆGEMIDLETS NAVN Incresync 12,5 mg/30 mg tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/30 mg tablets alogliptin/pioglitazone
6.1 eller en tidligere alvorlig overfølsomhedsreaktion, herunder anafylaktisk reaktion, 
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8)
LÆGEMIDLETS NAVN Incresync 25 mg/45 mg filmovertrukne tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/45 mg film-coated tablets alogliptin/pioglitazone
LÆGEMIDLETS NAVN Incresync 25 mg/30 mg filmovertrukne tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/30 mg film-coated tablets alogliptin/pioglitazone
Behandlingskorrigeret ændring i HbA1c fra baseline 
Treatment-corrected change from baseline in HbA1c (%)†
LÆGEMIDLETS NAVN Incresync 12,5 mg/45 mg filmovertrukne tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/45 mg film-coated tablets alogliptin/pioglitazone
LÆGEMIDLETS NAVN Incresync 12,5 mg/30 mg filmovertrukne tabletter alogliptin/pioglitazon 
NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/30 mg film-coated tablets alogliptin/pioglitazone
EU/1/13/842/001 10 filmovertrukne tabletter EU/1/13/842/002 14 filmovertrukne tabletter EU/1/13/842/003 28 filmovertrukne tabletter EU/1/13/842/004 30 filmovertrukne tabletter EU/1/13/842/005 56 filmovertrukne tabletter EU/1/13/842/006 60 filmovertrukne tabletter EU/1/13/842/007 90 filmovertrukne tabletter EU/1/13/842/008 98 filmovertrukne tabletter EU/1/13/842/009 100 filmovertrukne tabletter 
EU/1/13/842/001 10 film-coated tablets EU/1/13/842/002 14 film-coated tablets EU/1/13/842/003 28 film-coated tablets EU/1/13/842/004 30 film-coated tablets EU/1/13/842/005 56 film-coated tablets EU/1/13/842/006 60 film-coated tablets EU/1/13/842/007 90 film-coated tablets EU/1/13/842/008 98 film-coated tablets EU/1/13/842/009 100 film-coated tablets
EU/1/13/842/019 10 filmovertrukne tabletter EU/1/13/842/020 14 filmovertrukne tabletter EU/1/13/842/021 28 filmovertrukne tabletter EU/1/13/842/022 30 filmovertrukne tabletter EU/1/13/842/023 56 filmovertrukne tabletter EU/1/13/842/024 60 filmovertrukne tabletter EU/1/13/842/025 90 filmovertrukne tabletter EU/1/13/842/026 98 filmovertrukne tabletter EU/1/13/842/027 100 filmovertrukne tabletter 
EU/1/13/842/019 10 film-coated tablets EU/1/13/842/020 14 film-coated tablets EU/1/13/842/021 28 film-coated tablets EU/1/13/842/022 30 film-coated tablets EU/1/13/842/023 56 film-coated tablets EU/1/13/842/024 60 film-coated tablets EU/1/13/842/025 90 film-coated tablets EU/1/13/842/026 98 film-coated tablets EU/1/13/842/027 100 film-coated tablets
- Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, titandioxid (E171), rød jernoxid (E172), macrogol 8000, shellac, carnaubavoks og glycerol mono-oleat. 
- The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), red iron oxide (E172), macrogol 8000, shellac, carnauba wax and glycerol mono-oleate.
EU/1/13/842/028 10 filmovertrukne tabletter EU/1/13/842/029 14 filmovertrukne tabletter EU/1/13/842/030 28 filmovertrukne tabletter EU/1/13/842/031 30 filmovertrukne tabletter EU/1/13/842/032 56 filmovertrukne tabletter EU/1/13/842/033 60 filmovertrukne tabletter EU/1/13/842/034 90 filmovertrukne tabletter EU/1/13/842/035 98 filmovertrukne tabletter EU/1/13/842/036 100 filmovertrukne tabletter 
EU/1/13/842/028 10 film-coated tablets EU/1/13/842/029 14 film-coated tablets EU/1/13/842/030 28 film-coated tablets EU/1/13/842/031 30 film-coated tablets EU/1/13/842/032 56 film-coated tablets EU/1/13/842/033 60 film-coated tablets EU/1/13/842/034 90 film-coated tablets EU/1/13/842/035 98 film-coated tablets EU/1/13/842/036 100 film-coated tablets
EU/1/13/842/010 10 filmovertrukne tabletter EU/1/13/842/011 14 filmovertrukne tabletter EU/1/13/842/012 28 filmovertrukne tabletter EU/1/13/842/013 30 filmovertrukne tabletter EU/1/13/842/014 56 filmovertrukne tabletter EU/1/13/842/015 60 filmovertrukne tabletter EU/1/13/842/016 90 filmovertrukne tabletter EU/1/13/842/017 98 filmovertrukne tabletter EU/1/13/842/018 100 filmovertrukne tabletter 
EU/1/13/842/010 10 film-coated tablets EU/1/13/842/011 14 film-coated tablets EU/1/13/842/012 28 film-coated tablets EU/1/13/842/013 30 film-coated tablets EU/1/13/842/014 56 film-coated tablets EU/1/13/842/015 60 film-coated tablets EU/1/13/842/016 90 film-coated tablets EU/1/13/842/017 98 film-coated tablets EU/1/13/842/018 100 film-coated tablets
Filmovertræk 12,5 mg/30 mg filmovertrukne tabletter 
12.5 mg/30 mg film-coated tablets
4.4) - Ikke-udredt makroskopisk hæmaturi (se pkt. 
Current bladder cancer or a history of bladder cancer (see section 4.4) Uninvestigated macroscopic haematuria (see section 4.4)
- Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac, carnaubavoks og glycerol mono-oleat. 
- The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac, carnauba wax and glycerol mono-oleate.
- Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, titandioxid (E171), rød jernoxid (E172), macrogol 8000, shellac, og sort jernoxid (E172). 
- The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), red iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172).
- Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac, og sort jernoxid (E172). 
- The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172).
Du må ikke tage Incresync, hvis du er gravid eller ammer. 
Incresync should not be used during pregnancy or breast-feeding.
• Indlægsseddel 
• The package leaflet
Dette sammendrag blev senest ajourført i 06-2016. 
This summary was last updated in 06-2016.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Vizamyl den 22. august 2014. 
The European Commission granted a marketing authorisation valid throughout the European Union for Vizamyl on 22 August 2014.
Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Vizamyl. 
This is a summary of the European public assessment report (EPAR) for Vizamyl.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vizamyl findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR and risk management plan summary for Vizamyl can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Der er udarbejdet en risikostyringsplan for at sikre, at Vizamyl anvendes så sikkert som muligt. 
A risk management plan has been developed to ensure that Vizamyl is used as safely as possible.
Andre oplysninger om Vizamyl 
Other information about Vizamyl
Hvad er Vizamyl, og hvad anvendes det til? 
What is Vizamyl and what is it used for?
Der blev efterfølgende foretaget en fornyet analyse af data fra de oprindelige 68 patienter sammenlagt med resultaterne fra dem, der var døde efter afslutningen af den oprindelige undersøgelse, i alt 106 patienter. 
A later re-analysis looked again at data from the original 68 patients together with results from others who had died after the end of the original study, making a total of 106 patients.
I denne fornyede analyse kunne de fleste af undersøgerne tolke skanningerne med en følsomhed på ca. 91 % (91 % af de patienter, der havde plak, blev identificeret), og en specificitet på 90 % (90 % af de patienter, der ikke havde plak, blev korrekt vurderet til at være uden plak). 
In this re-analysis most readers could interpret the scans with a sensitivity of around 91% (91% of patients who had plaques were identified) and a specificity of 90% (90% of patients without plaques were correctly rated as not having plaques).
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Vizamyl? 
What measures are being taken to ensure the safe and effective use of Vizamyl?